What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?
Lamoth
Frédéric
F
Manuel
Oriol
O
Venetz
Jean-Pierre
JP
Faouzi
Mohamed
M
Meylan
Pascal
P
Pascual
Manuel
M
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000517:prevention & control*; D005500:Follow-Up Studies; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation; D009894:Opportunistic Infections / Q000453:epidemiology / Q000517:prevention & control; D000077562:Valganciclovir
D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir